EXACT Sciences (EXAS) Stock Price Down 0%

EXACT Sciences Co. (NASDAQ:EXAS)’s share price fell 0% during trading on Monday . The company traded as low as $48.63 and last traded at $49.90. 7,630,000 shares changed hands during trading, an increase of 412% from the average session volume of 1,490,000 shares. The stock had previously closed at $49.90.

A number of research firms have commented on EXAS. Leerink Swann restated an “outperform” rating and set a $50.00 price objective (up previously from $45.00) on shares of EXACT Sciences in a research note on Thursday, September 21st. BidaskClub upgraded EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Canaccord Genuity restated a “buy” rating and set a $60.00 price objective (up previously from $45.00) on shares of EXACT Sciences in a research note on Tuesday, October 3rd. Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price objective on the stock in a research note on Tuesday, September 26th. Finally, Robert W. Baird restated a “buy” rating and set a $49.00 price objective on shares of EXACT Sciences in a research note on Friday, October 6th. Eight analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $79.71.

The company has a market capitalization of $5,980.00, a price-to-earnings ratio of -43.39 and a beta of 0.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. The firm had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company’s revenue was up 158.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.36) EPS. research analysts forecast that EXACT Sciences Co. will post -1.1 EPS for the current year.

In related news, CEO Kevin T. Conroy sold 137,805 shares of the firm’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the sale, the chief executive officer now owns 967,867 shares of the company’s stock, valued at approximately $57,239,654.38. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Graham Peter Lidgard sold 45,775 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $53.60, for a total value of $2,453,540.00. Following the sale, the insider now directly owns 272,819 shares in the company, valued at approximately $14,623,098.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 610,433 shares of company stock worth $34,341,306. Company insiders own 4.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Chicago Equity Partners LLC acquired a new stake in shares of EXACT Sciences during the 3rd quarter valued at $2,312,000. Bank of Nova Scotia acquired a new stake in shares of EXACT Sciences during the 2nd quarter valued at $1,482,000. Federated Investors Inc. PA boosted its holdings in shares of EXACT Sciences by 53.3% during the 2nd quarter. Federated Investors Inc. PA now owns 34,553 shares of the medical research company’s stock valued at $1,222,000 after acquiring an additional 12,018 shares in the last quarter. Stifel Financial Corp boosted its holdings in shares of EXACT Sciences by 16.5% during the 2nd quarter. Stifel Financial Corp now owns 25,023 shares of the medical research company’s stock valued at $888,000 after acquiring an additional 3,548 shares in the last quarter. Finally, Sit Investment Associates Inc. boosted its holdings in shares of EXACT Sciences by 168.2% during the 3rd quarter. Sit Investment Associates Inc. now owns 29,900 shares of the medical research company’s stock valued at $1,409,000 after acquiring an additional 18,750 shares in the last quarter. 82.39% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “EXACT Sciences (EXAS) Stock Price Down 0%” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2018/01/08/exact-sciences-exas-stock-price-down-0.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit